Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.
Identifieur interne : 000355 ( Main/Corpus ); précédent : 000354; suivant : 000356Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.
Auteurs : Maarten J. Postma ; Paul Jansema ; Huib W K F H. Scheijbeler ; Marianne L L. Van GenugtenSource :
- Vaccine [ 0264-410X ] ; 2005.
English descriptors
- KwdEn :
- Absenteeism (MeSH), Adolescent (MeSH), Adult (MeSH), Age Factors (MeSH), Aged (MeSH), Cohort Studies (MeSH), Cost Savings (MeSH), Costs and Cost Analysis (MeSH), Efficiency (MeSH), Employment (economics), Female (MeSH), Humans (MeSH), Influenza, Human (economics), Influenza, Human (prevention & control), Influenza, Human (therapy), Male (MeSH), Middle Aged (MeSH), Models, Economic (MeSH), Monte Carlo Method (MeSH), Netherlands (MeSH).
- MESH :
- geographic : Netherlands.
- economics : Employment, Influenza, Human.
- prevention & control : Influenza, Human.
- therapy : Influenza, Human.
- Absenteeism, Adolescent, Adult, Age Factors, Aged, Cohort Studies, Cost Savings, Costs and Cost Analysis, Efficiency, Female, Humans, Male, Middle Aged, Models, Economic, Monte Carlo Method.
Abstract
OBJECTIVE
To assess the economic implications of strategies for influenza control among healthy working adults in The Netherlands.
METHODS
The economic evaluation was based on a pharmaco-economic model from the societal perspective. This model involves the direct and indirect costs of vaccination or treatment and the direct and indirect savings (averted costs) due to the control strategy. Control strategies comprised treatment with oseltamivir and prevention with the influenza vaccine. Clinical and economic parameter estimates were derived from published literature, databases and expert opinions. Several scenarios for age-groups and employment contracts (full-time versus not) were elaborated in combination with Monte Carlo simulation for probabilistic sensitivity analysis.
RESULTS
Consistently, net cost savings are estimated over the range of age groups and scenarios considered. Net savings are smallest for half-time workers. Incremental analysis indicates that on average prevention renders higher cost savings than treatment.
CONCLUSION
We found a consistent picture of net cost savings for prevention through vaccination and treatment with oseltamivir of influenza in healthy working adults in The Netherlands.
DOI: 10.1016/j.vaccine.2005.06.007
PubMed: 16029916
Links to Exploration step
pubmed:16029916Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.</title><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name><affiliation><nlm:affiliation>Groningen University Institute for Drug Exploration/University of Groningen Research Institute for Pharmacy (GUIDE/GRIP), Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. m.j.postma@rug.nl</nlm:affiliation></affiliation></author><author><name sortKey="Jansema, Paul" sort="Jansema, Paul" uniqKey="Jansema P" first="Paul" last="Jansema">Paul Jansema</name></author><author><name sortKey="Scheijbeler, Huib W K F H" sort="Scheijbeler, Huib W K F H" uniqKey="Scheijbeler H" first="Huib W K F H" last="Scheijbeler">Huib W K F H. Scheijbeler</name></author><author><name sortKey="Van Genugten, Marianne L L" sort="Van Genugten, Marianne L L" uniqKey="Van Genugten M" first="Marianne L L" last="Van Genugten">Marianne L L. Van Genugten</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16029916</idno><idno type="pmid">16029916</idno><idno type="doi">10.1016/j.vaccine.2005.06.007</idno><idno type="wicri:Area/Main/Corpus">000355</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000355</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.</title><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name><affiliation><nlm:affiliation>Groningen University Institute for Drug Exploration/University of Groningen Research Institute for Pharmacy (GUIDE/GRIP), Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. m.j.postma@rug.nl</nlm:affiliation></affiliation></author><author><name sortKey="Jansema, Paul" sort="Jansema, Paul" uniqKey="Jansema P" first="Paul" last="Jansema">Paul Jansema</name></author><author><name sortKey="Scheijbeler, Huib W K F H" sort="Scheijbeler, Huib W K F H" uniqKey="Scheijbeler H" first="Huib W K F H" last="Scheijbeler">Huib W K F H. Scheijbeler</name></author><author><name sortKey="Van Genugten, Marianne L L" sort="Van Genugten, Marianne L L" uniqKey="Van Genugten M" first="Marianne L L" last="Van Genugten">Marianne L L. Van Genugten</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absenteeism (MeSH)</term><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Cost Savings (MeSH)</term><term>Costs and Cost Analysis (MeSH)</term><term>Efficiency (MeSH)</term><term>Employment (economics)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (therapy)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Models, Economic (MeSH)</term><term>Monte Carlo Method (MeSH)</term><term>Netherlands (MeSH)</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Employment</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absenteeism</term><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Cohort Studies</term><term>Cost Savings</term><term>Costs and Cost Analysis</term><term>Efficiency</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Models, Economic</term><term>Monte Carlo Method</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To assess the economic implications of strategies for influenza control among healthy working adults in The Netherlands.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The economic evaluation was based on a pharmaco-economic model from the societal perspective. This model involves the direct and indirect costs of vaccination or treatment and the direct and indirect savings (averted costs) due to the control strategy. Control strategies comprised treatment with oseltamivir and prevention with the influenza vaccine. Clinical and economic parameter estimates were derived from published literature, databases and expert opinions. Several scenarios for age-groups and employment contracts (full-time versus not) were elaborated in combination with Monte Carlo simulation for probabilistic sensitivity analysis.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Consistently, net cost savings are estimated over the range of age groups and scenarios considered. Net savings are smallest for half-time workers. Incremental analysis indicates that on average prevention renders higher cost savings than treatment.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>We found a consistent picture of net cost savings for prevention through vaccination and treatment with oseltamivir of influenza in healthy working adults in The Netherlands.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16029916</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>46-47</Issue><PubDate><Year>2005</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.</ArticleTitle><Pagination><MedlinePgn>5365-71</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the economic implications of strategies for influenza control among healthy working adults in The Netherlands.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The economic evaluation was based on a pharmaco-economic model from the societal perspective. This model involves the direct and indirect costs of vaccination or treatment and the direct and indirect savings (averted costs) due to the control strategy. Control strategies comprised treatment with oseltamivir and prevention with the influenza vaccine. Clinical and economic parameter estimates were derived from published literature, databases and expert opinions. Several scenarios for age-groups and employment contracts (full-time versus not) were elaborated in combination with Monte Carlo simulation for probabilistic sensitivity analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Consistently, net cost savings are estimated over the range of age groups and scenarios considered. Net savings are smallest for half-time workers. Incremental analysis indicates that on average prevention renders higher cost savings than treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found a consistent picture of net cost savings for prevention through vaccination and treatment with oseltamivir of influenza in healthy working adults in The Netherlands.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Postma</LastName><ForeName>Maarten J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Groningen University Institute for Drug Exploration/University of Groningen Research Institute for Pharmacy (GUIDE/GRIP), Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. m.j.postma@rug.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansema</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Scheijbeler</LastName><ForeName>Huib W K F H</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>van Genugten</LastName><ForeName>Marianne L L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000041" MajorTopicYN="N">Absenteeism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017046" MajorTopicYN="N">Cost Savings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004526" MajorTopicYN="N">Efficiency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>06</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16029916</ArticleId><ArticleId IdType="pii">S0264-410X(05)00585-2</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2005.06.007</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000355 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000355 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:16029916
|texte= Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:16029916" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |